2-(tetrahydro-2-pyranyloxy)propyl tosylate | 93713-83-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(tetrahydro-2-pyranyloxy)propyl tosylate
• 英文别名: 1-(p-toluenesulfonoxy)-2-<(tetrahydro-2-pyranyl)oxy>propane；1-Propanol, 2-[(tetrahydro-2H-pyran-2-YL)oxy]-, 4-methylbenzenesulfonate, (2S)-；2-(oxan-2-yloxy)propyl 4-methylbenzenesulfonate
• CAS: 93713-83-8
• 化学式: C₁₅H₂₂O₅S
• 分子量: 314.403
• InChiKey: CIRBILLHZJTIAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  70.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(tetrahydro-2-pyranyloxy)propyl tosylate 、 二乙二醇 在 sodium hydride 作用下， 生成 2-[1-[2-[2-[2-(oxan-2-yloxy)propoxy]ethoxy]ethoxy]propan-2-yloxy]oxane
  参考文献：
  名称：

  Alkali metals dissolved in optically active solvents

  摘要：

  DOI：

  10.1021/jo00323a026
• 作为产物：
  描述：

  乳酸乙酯 生成 2-(tetrahydro-2-pyranyloxy)propyl tosylate
  参考文献：
  名称：

  ISIBASI, SIGEHKI;NAKAMURA, KODZABURO;NAKAXATA, MASAAKI;NEHGISI, TAKAAKI;U+

  摘要：

  DOI：

文献信息

• Substituted Pyridine Compound
  申请人：Nakamura Tsuyoshi

  公开号：US20130109653A1

  公开（公告）日：2013-05-02

  The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R 1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

  本发明提供了一种取代吡啶化合物或其药理学上可接受的盐，具有优异的CETP抑制活性，并可用作药物。本发明提供了一种由通式（I）表示的化合物，其中R1为H，可选地取代的烷基，OH，可选地取代的烷氧基，烷基磺酰基，可选地取代的氨基，羧基，可选地取代的羰基，CN，卤素，可选地取代的苯基，可选地取代的芳香杂环基，可选地取代的饱和杂环基，可选地取代的饱和杂环氧基或可选地取代的饱和杂环羰基等。
• Substituted Piperazines as CB1 Antagonists
  申请人：Gilbert Eric J.

  公开号：US20090105208A1

  公开（公告）日：2009-04-23

  Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB 1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  式(I)的化合物或其药学上可接受的盐、溶剂化物或酯类，可用于治疗由CB1受体介导的疾病或症状，例如代谢综合征和肥胖症、神经炎症性疾病、认知障碍和精神病、成瘾（例如戒烟）、胃肠疾病和心血管疾病。
• Substituted PyridineCompound
  申请人：Nakamura Tsuyoshi

  公开号：US20140005143A2

  公开（公告）日：2014-01-02

  The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein R 1 is H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

  本发明提供了一种替代吡啶化合物或其药学上可接受的盐，具有优异的CETP抑制活性，并可用作药物。本发明提供了一种由通式（I）表示的化合物，其中R1为H、可选取代烷基、OH、可选取代烷氧基、烷基磺酰基、可选取代氨基、羧基、可选取代羰基、CN、卤素、可选取代苯基、可选取代芳香杂环基、可选取代饱和杂环基、可选取代饱和杂环氧基或可选取代饱和杂环羰基等。
• AMINO-QUINOLINES AS KINASE INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20150094333A1

  公开（公告）日：2015-04-02

  Disclosed are compounds having the formula: wherein R 1 , R 2 R 3 , R 4 and R 5 are as defined herein, and methods of making and using the same.

  公开了具有以下式子的化合物：其中R1，R2，R3，R4和R5的定义如本文所述，并且公开了制备和使用这些化合物的方法。
• Substituted piperazines as CB1 antagonists
  申请人：Intervet International B.V.

  公开号：EP2548874A2

  公开（公告）日：2013-01-23

  Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB, receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

  式 (I) 的化合物： 或其药学上可接受的盐、溶液剂或酯类，可用于治疗由 CB 受体介导的疾病或病症，如代谢综合征和肥胖症、神经炎性疾病、认知障碍和精神病、成瘾（如戒烟）、胃肠道疾病和心血管疾病。